Items tagged with Access
TB-LAMP test now available for $6 through Global Drug Facility (post)
02 March 2020, Geneva, Switzerland - Stop TB Partnership’s Global Drug Facility (GDF), Eiken Chemical Co., Ltd (Eiken) and Human Gesellschaft für Biochemica und Diagnostica mbH (HUMAN) announced today an agreement to reduce the price of the TB-LAMP test by over 30%.
Coronavirus disruptions could hurt North Korea’s efforts to treat TB (post)
North Korea watchers warn that the country’s aggressive measures to defend itself against COVID-19, the illness caused by the novel coronavirus, are hobbling efforts to combat tuberculosis (TB) and other infectious diseases.
TB drug delamanid fast drying out, India yet to receive new stocks from Japan (post)
Indian Government is now looking to buy delamanid for the first time from Otsuka.
WHO Information Note: Ensuring continuity of TB services during the COVID-19 pandemic (post)
20 March 2020 | GENEVA: As the world comes together to tackle the COVID-19 pandemic, it is important to ensure that essential health services and operations are continued to protect the lives of people with TB and other diseases or health conditions. Health services, including national programmes to combat TB, need to be actively engaged in ensuring an effective and rapid response to COVID-19 while ensuring that TB services are maintained.
EMA panel backs pretomanid for drug-resistant TB (post)
The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has recommended approval of pretomanid FGK (FGK Representative Service GmbH) for drug-resistant tuberculosis (TB).
Webinar recording: Fair pricing for Cepheid Xpert tests (COVID-19, HIV, TB, HCV) (post)
On 3 April 2020, Treatment Action Group (TAG), Médecins Sans Frontières (MSF) Access Campaign, and the Global Coalition of TB Activists (GCTA) held a webinar on the price of Xpert tests for COVID-19, HIV, TB, HCV and other diseases. The webinar provided the latest information about the “Time for $5” campaign and the evidence base for why GeneXpert tests should be priced at US$5.
TB response is heavily impacted by the COVID-19 pandemic (post)
The Stop TB Partnership Secretariat organized a rapid assessment of the impact the COVID-19 pandemic and related measures have on the TB response in 20 high burden countries that represent 54% of the global TB burden, through interviews with National TB Programs (NTPs) and focal points based on a set of open-ended questions. Similarly, the Global Coalition of TB Activists (GCTA) did a worldwide survey through their network of members collecting answers from TB civil society and communities from 16 countries, with data updated regularly.
Stop TB Partnership launches tools for TB programs and TB communities on TB and COVID-19 (post)
As the COVID-19 pandemic spreads across the world, countries are rushing to put in place strategies to ease the burden on health systems and to mitigate disruption in routine health services. The current social distancing and stay-at-home measures will make it particularly challenging for tuberculosis (TB) programs to provide the necessary diagnosis, treatment and care for the people and communities affected by TB.
Virtual Innovation Spotlights on health tech solutions for TB and COVID-19 (post)
To support country programs, communities, people affected by TB, and partners during the COVID-19 pandemic, the Stop TB Partnership’s Strategic Initiatives & Innovative Financing (SIIF) Team, as part of its Re-Imagining TB Care initiative, is organising a series of Virtual Innovation Spotlights to share various health tech solutions that can be used to:
New, shorter treatment to prevent TB to be rolled out in five high-burden TB countries (post)
Three-month regimen expected to prevent TB in those at highest risk of developing the disease, including people living with HIV and children under the age of five.
Page 41 of 83 · Total posts: 0
←First 40 41 42 Last→